Alopecia Areata - Pipeline Insight, 2024

This “Alopecia Areata- Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Alopecia Areata: Understanding

Alopecia Areata: Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.

Alopecia areata is a disorder of hair follicle-cycling, where inflammatory cells attack the hair follicle matrix epithelium that is undergoing early cortical differentiation (anagen hair follicles), which are then precipitately induced into the catagen phase. However, since no destruction of hair-follicle stem cells occurs, the hair follicle retains its capacity to regenerate and continue cycling. Thereby, follicles re-enter the anagen phase normally but do not develop beyond the anagen III/IV phase.

Presumably, alopecia areata develops in a previously healthy hair follicle because its immune privilege collapses. Therefore, it could occur in a genetically predisposed person only when proinflammatory signals (i.e., IFN gamma, substance P) known to upregulate MHC class Ia in human hair-follicle epithelium expose previously unrevealed follicle-associated autoantigens to preexisting autoreactive CD8+ T cells. Since only anagen hair follicles undergo attack, those auto antigens may generate and then be presented only during anagen. The precise event that precipitates alopecia areata is unknown. Some triggers have been reported, most commonly emotional or physical stress, vaccines, viral infections, and drugs.

Many therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes.

Alopecia Areata- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alopecia Areata pipeline landscape is provided which includes the disease overview and Alopecia Areata treatment guidelines. The assessment part of the report embraces, in depth Alopecia Areata commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia Areata collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia Areata R&D. The therapies under development are focused on novel approaches to treat/improve Alopecia Areata.

Alopecia Areata Emerging Drugs Chapters

This segment of the Alopecia Areata report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alopecia Areata Emerging Drugs

Deuruxolitinib: Concert PharmaceuticalsConcert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

EQ101: EquilliumEQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

MAX 40070: Maxinovel PharmaceuticalsMAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

Alopecia Areata: Therapeutic Assessment

This segment of the report provides insights about the different Alopecia Areata drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alopecia Areata

• There are approx. 18+ key companies which are developing the therapies for Alopecia Areata. The companies which have their Alopecia Areata drug candidates in the most advanced stage, i.e. phase III include, Concert Pharmaceuticals.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alopecia Areata: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alopecia Areata therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alopecia Areata drugs.

Alopecia Areata Report Insights

• Alopecia Areata Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alopecia Areata Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alopecia Areata drugs?
• How many Alopecia Areata drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alopecia Areata?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alopecia Areata therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alopecia Areata and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Concert Pharmaceuticals
• Equillium
• Maxinovel Pharmaceuticals
• TechnoDerma Medicines
• Sichuan Kelun-Biotech Biopharmaceutical
• Pfizer
• Reistone Biopharma Company Limited

Key Products

• Deuruxolitinib
• EQ101
• MAX 40070
• TDM-105795
• KL130008
• PF-06651600
• SHR0302

This product will be delivered within 1-3 business days.